Safety and Activity of SNX-5422 Plus Ibrutinib in CLL

Exclusion Criteria

• •Subjects experiencing toxicity with ibrutinib
• •Prior treatment with any Hsp90 inhibitor.
• •Major surgery or significant traumatic injury within 4 weeks of starting study treatment.
• •Conventional chemotherapy or radiation within 4 weeks.
• •The need for treatment with medications with clinically-relevant metabolism by the cytochrome P450 (CYP) 3A4 isoenzyme within 3 hours before or after administration of SNX-5422
• •Screening ECG QTc interval 470 msec for females, 450 msec for males.
• •At increased risk for developing prolonged QT interval unless corrected to within normal limits prior to first dose of SNX-5422
• •Patients with chronic diarrhea or with Grade 2 or greater diarrhea despite appropriate medical management.
• •Gastrointestinal diseases or conditions that could affect drug absorption
• •Gastrointestinal diseases that could alter the assessment of safety, including irritable bowel syndrome, ulcerative colitis, Crohn's disease, or hemorrhagic coloproctitis.
• •History of documented adrenal dysfunction not due to malignancy.
• •History of chronic liver disease.
• •Active hepatitis A or B.
• •Current alcohol dependence or drug abuse.
• •Use of an investigational treatment (except for ibrutinib) from 30 days prior to the first dose
• •Glaucoma, retinitis pigmentosa, macular degeneration, or any retinal changes detected by ophthalmological examination that are considered clinically important by examiner.
• •Psychological or social reasons that would hinder or prevent compliance with the requirements of the protocol or compromise the informed consent process.